Related Experiment Video
Updated: Apr 3, 2026
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics
Deborah Barthel1, Gerd Ganser2, Rolf-Michael Kuester2
1From the Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin; Department of Pediatric Rheumatology, St. Josef-Stift Sendenhorst, Sendenhorst; Asklepios Rheumazentrum Hamburg, Hamburg; Pediatric Practice, Lueneburg; Deutsches Rheuma-Forschungszentrum, Berlin; Department of Pediatrics, Vivantes Klinikum im Friedrichshain, Berlin; Department of Pediatrics, Klinikum Stuttgart, Stuttgart, Germany.D. Barthel, MD, Department of Pediatrics, Asklepios Klinik Sankt Augustin; G. Ganser, MD, Department of Pediatric Rheumatology, St. Josef-Stift Sendenhorst; R.M. Kuester, MD, Senior Consultant, Asklepios Rheumazentrum Hamburg; N. Onken, MD, Pediatric Practice; K. Minden, MD, Deutsches Rheuma-Forschungszentrum; H.J. Girschick, MD, Department of Pediatrics, Vivantes Klinikum im Friedrichshain; A. Hospach, MD, Department of Pediatrics, Klinikum Stuttgart; G. Horneff, MD, Department of Pediatrics, Asklepios Klinik Sankt Augustin. d.barthel@asklepios.com.
Objective:
Evolving inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) and might be associated with JIA therapy.
Methods:
Data from the German biologics registry (Biologika in der Kinderrheumatologie; BiKeR) from 2001 to 2013 were analyzed.
Results:
There were 3071 patients with 8389 patient-years (PY) of observation followed. IBD was diagnosed in 11 patients, 8 with Crohn disease and 3 with ulcerative colitis. IBD incidence in patients with JIA was 1.31/1000 PY and higher than published IBD incidences in pediatric populations. Compared with the total BiKeR cohort, patients with IBD more commonly had enthesitis-related arthritis, extended oligoarthritis, psoriatic arthritis, and also rheumatoid factor (RF)-negative polyarthritis. No IBD occurred in patients with systemic JIA or RF-positive polyarthritis. In patients treated with methotrexate (MTX), the IBD incidence was significantly lower compared with patients not treated with MTX. Etanercept (ETN) monotherapy, but not the combination of ETN and MTX, was associated with an increased incidence of IBD.
Conclusion:
Incidence of IBD in patients with JIA is higher than in the population. MTX turned out to be protective, even in combination with ETN.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...